After Glenmark, Cipla promises cheaper Favipiravir for treatment of COVID-19 patients

▴ After Glenmark, Cipla promises cheaper Favipiravir for treatment of COVID-19 patients
After Glenmark, Cipla is ready with their version of cheaper Favipiravir

After Indian pharma firm Glenmark Pharmaceuticals launched antiviral drug Favipiravir as "FabiFlu" for COVID-19 patients on last Saturday for patients with mild and moderate symptoms, another multi-center Phase-II drug trial being done by the Council of Scientific and Industrial Research (CSIR) shows that its drug can cost lesser by at least 20-30 percent of the current price.

A source aware of the development said to India Today, "Our projection is 20-30 per cent lesser than the current price point." As per the results, it could lead to a major reduction in the cost of the drug required for the treatment of mild and moderate symptoms of coronavirus.

The CSIR had done end-to-end synthesis of Favipiravir in April. It is now conducting multi-centre Phase-II trials of the drug with Mumbai-based pharma company Cipla which is due to make public the trial results soon.

Meanwhile, Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19. Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to moderate COVID-19. The antiviral offers broad-spectrum RNA virus coverage2 with clinical improvement noted across age groups 20 to >90 years.3 Favipiravir can be used in COVID-19 patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID 19 symptoms.It offers a rapid reduction in viral load within 4 days, and provides faster symptomatic and radiological improvement. Of most importance, Favipiravir has shown clinical improvement of up to 88% in COVID-19 mild to moderate COVID 19 cases.

Faviflu is priced at Rs 103 per tablet wit strip of 34 costing Rs3,500 while Cipla claimed that they will be launching the drug at 20% to 30% cheaper due to the synthetic technology employed.

CSIR has identified top 25 drugs/drug candidates for repurposing to provide drugs for coronavirus patients in India. Among these top 25 drugs, Favipiravir, a broad-spectrum inhibitor of viral RNA polymerase, has emerged as one of the most promising drugs.

According to the latest figures from Health Ministry, the number of patients recovering from COVID-19 continues to increase. So far, a total of 2,27,755 patients have been cured. During the last 24 hours, a total of 13,925 COVID-19 patients have been cured. The recovery rate has further improved to 55.49% amongst COVID-19 patients. Presently, there are 1,69,451 active cases and all are under active medical supervision.

Today, the number of recovered patients has crossed the number of active patients by 58,305. The number of government labs has been increased to 722 and private labs has been increased to 259 (a total of 981). The number of samples being tested every day also continues to grow. In the last 24 hours, 1,90,730 samples were tested. The total number of samples tested thus far is 68,07,226.

With Story Input from India Today

Tags : #Cipla #Glenmark #CSIR #Favipiravir #IndiaToday #PharmaNews #Antiviral #CheaperFavipiravir #PharmaUpdate #CovidNews #CovidCureUpdate #ICMR

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026